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Abstract
Analysis of the literature data on alcoholic addiction, poststress maladjustment and its combination revealed the 
significant number of common node moments in pathogenic mechanisms of its appearing and realization. It concerns 
biological mechanisms that are common for both processes and its activation at one of them provokes the development of 
the other. First of all it is stem structures of brain and neuroendocrine mechanisms of central and peripheral regulation 
and its activation is cross for stressor reaction and alcoholization. There was revealed the leading role of stressor reaction 
mechanisms and its association with poststress maladjustment in formation of psychological alcoholic addiction. There 
was constructed hypothetical model of development and functioning of association pathogenetic mechanisms with for-
mation of comorbidity of analyzed pathological states. 
Keywords: poststress maladjustment, alcoholic addiction, stressor reaction, psychic mechanisms, vegetative reg-
ulation, comorbidity. 
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1. Introduction
Data received in the recent years using morphological, immunological and neuroimaging re-
search methods have greatly changed the traditional notion of multiple sclerosis (MS) as a remittent 
central nervous system (CNS) disease causing destruction of myelin of brain and spinal cord conduc-
tors only. It turned out that the pathological process continues even in the phase of clinical remission; 
axons are damaged from the initial stage of disease; besides the CNS white matter, grey matter of the 
cortex and subcortex is also damaged. However, a number of issues still remain unsolved. Different 
clinical courses of MS, heterogeneity of its clinical implications, different effect of immunomodulato-
ry therapy for the same clinical forms implies various pathogenetic mechanisms of the CNS damage 
in this disease [1–5]. The scientific and practical objective in researching MS lies in studying mecha-
nisms of neurodegenerative process development, assessment of interrelation between inflammatory, 
immunopathological and degenerative processes. There have not yet been established any informative 
immunobiochemical markers allowing the monitoring of pathological process activity at different MS 
courses using process activity estimates and prognosis; mechanisms that trigger exacerbations and re-
mission are not clear either. Applicability of immunological and biochemical markers for the estimation 
of immunocorrecting and anti-inflammatory therapy efficacy is disputable [6–8]. Many of the proposed 
methods are complicated, laborious and costly. In this respect, it deems relevant to look for informative 
and widely available markers suitable for pathological process monitoring and prediction. 
Search for new, more efficient MS treatment methods is closely related to the profound re-
search of pathogenesis links of the disease, many aspects of which still unclear. In particular, the 
role of matrix metalloproteinase (MMP) which is normally a physiological mediator of tissues re-
modeling in MS pathogenesis has not been sufficiently studied. Most of the investigations are based 
on experiments on animals and MMP in vitro studies [9–12]. One of the main pathogenetic links 
in MS such as blood-brain barrier (BBB) disruption and as a result migration of plasma proteins to 
the brain parenchyma is MMP. MMPs form a series of enzymes whose principal activity is remod-
eling of the intercellular matrix. MMP-9 or gelatinase В is the most complicated metalloproteinase 
in terms of its domain structure and activity regulation. MMP-9 activity is strictly regulated at 
the different levels: regulation of genetic transcription by cytokines and various cellular interac-
tions; regulation of proenzyme activation by the enzyme cascade including serine proteases and 
other MMPs; regulation by specific tissue inhibitors of MMPs (TIMPs) or non-specific inhibitors. 
MMP’s main function is degradation of extracellular matrix components. 
Matrix metalloproteinases are involved in multiple processes represented in Table 1.
Scholars attach great importance to MMPs when studying inflammations. It is known that 
most cells involved in immune reactions and inflammation (T-lymphocytes, macrophages, eosin-
ophils and neutrophils) produce certain MMPs [13–16]. MMP production depends on different in-
flammatory mediators. MMP synthesis in macrophages for example is induced by contact with col-
lagen and is further intensified by T-lymphocyte membrane determinants. Through matrix damage 
MMPs prepare the vascular wall to the adhesion of immune cells and facilitate migration of cells, 
proteins, antibodies, complement, etc. through the basal membrane to tissues [17–19]. According 
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to the latest publications MMPs are very important for CNS development and differentiation and 
may be produced by neurons [20, 21]. Besides through ECM remodeling it can influence different 
functions of the nerve tissue and growth factor concentration as well as impact synapse formation 
and stabilization and further interneuronic and neuroglia interaction. 
Table 1
MMP’s role in remodeling extracellular matrix (ECM) [6]
PHYSIOLOGICAL PROCESSES PATHOLOGICAL PROCESSES
Ovulation Growth/metastatic dissemination of tumorsTrophoblast and blastocyst implantation
Embryogenesis Rheumatoid arthritis, osteoarthritis
Morphogenesis of salivary glands Periodontium disease
Development/involution of mammary glands
Pulmonary fibrosis
Liver cirrhosis
Dilatation of cervix uteri Gastric and stercoral ulcer
Uterine involution Dilatational cardiomyopathy
Development/alteration of bones Atherosclerosis
Healing of wounds/fractures Arterial aneurism
Angiogenesis Glomerulonephritis
Functioning of macrophages/ neutrophils Encephalomyelitis
There are studies dedicated to MMP’s role in metastatic dissemination of CNS tumors, stroke, 
neurodegenerative and demyelinization diseases. Some studies deal with MMPs’ activity and inten-
sity in infectious diseases of the CNS. MMP’s role in bacterial meningitis is paid special attention to. 
The fundamental pathogenetic mechanism causing secondary damage at demyelinization diseases is 
BBB disruption. There are a lot of inflammation mediators that are known to play a certain role in 
BBB disruption. These are above all radicals of oxygen, nitrogen oxide, metabolites of arachidonic 
acid (E2 prostaglandines) and cytokines such as TNF-α, interleukin (IL)-1 β, IL-6 and IL-10 [22, 23]. 
However mechanisms of BBB disruption have not yet received comprehensive examination. 
Thus on the one hand MMPs are physiological mediators important for CNS growth, devel-
opment and functioning and on the other hand they are proteolytic enzymes that actively interact 
with cellular and humoral factors of the immune system (epidermal growth factor, growth factor of 
thrombocyte origin, IL-1, IL-4, etc.) and trigger pathological processes.
This research aims at improvement of pathological process stages diagnostics at multiple 
sclerosis and further therapy optimization depending on the activity of inflammatory process. 
2. Research materials and methods
135 patients (54 males and 81 females) of different age (from 18 to 67) with multiple sclero-
sis (diagnosed according to the McDonald criteria, 2010) of different course types and at different 
activity stages of the pathological process were examined.
Quantitative determination of MMP-9 concentration was performed in the blood serum 
using an immune-enzyme test kit (Human MMP-9 ELISA, Bio Tech Lab-S).
3. Results and discussion
The highest MMP-9 rate was observed in patients with relapsing-remittent multiple sclero-
sis (RRMS) (average rate ММР-9av=212.37±17.51). The lowest rate was in patients with primary 
progressive MS (PPMS) (ММР-9av=135.33±6.87). The medium rate was in patients with secondary 
progressive (SPMS) (ММР-9av=252.19±10.36). Obtained factor is F=5.238; its statistical signifi-
cance is р<0.01. ANOVA variance analysis was used to determine interrelation between the clinical 
course type and MMP-9 rate; graphic results are provided in Fig. 1. 
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Fig. 1. Dependence of MMP-9 rate on the clinical course type
Besides the metalloproteinase rate was analyzed at different activity stages of the patholog-
ical process (exacerbation and remission in RRMS, progression and stabilization in progredient 
course types). Average MMП-9av rates for the groups under examination were as follows: in RRMS 
at the remission stage – 122.05±7.82, at the exacerbation stage – 378.68±21.54. In progredient 
course types: at the stage of progression – 164.73±12.21, at the stage of stabilization – 114.64±8.43. 
The data obtained can be found in Fig. 2.
Fig. 2. Dependence of MMP-9 rate on the clinical course type
The value of factor F is so high that probability of error was almost equal to zero (р<0.0001). It 
is shown on the graph that the highest MMP-9 rates were observed at the exacerbation and progression 
stages of the pathological process. At the stages of remission and stabilization MMP-9 rates were 
within the normal range. Thus it was proved with a high degree of confidence that the average 
MMP-9 rate depends on the stage of disease.
MMP-9 rate is influenced by all of the factors collectively but not individually. Therefore 
clinical course types and disease stages as factors influencing MMP-9 rate most of all were ana-
lyzed using the multi-factor variance analysis. The results obtained are given in Table 2.
According to Table 2, the highest MMP-9 rates were observed in the RRMS group at the 
stage of disease exacerbation (381.54±22.19). MMP-9 rate was within the normal range at the stage 
of remission and reached 122.05±7.82. MMP-9 rates were high at the active stage in SPMS and 
PPMS: 169.98±15.64 and 147.03±6.78 respectively. The results obtained proved that inflammatory 
reactions in SPMS are more apparent than in PPMS when neurodegeneration processes are of pri-
mary importance. Unexpectedly MMP-9 rates at the stage of stabilization were higher in PPMS 
(121.96±10.90) than in SPMS (114.64±8.43). This may be accounted for by a considerable difference 
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between the number of patients in the respective groups – there were three times fewer patients 
in the PPMS group at the stage of stabilization than in the SPMS group at the same stage. The ob-
tained results are represented graphically in Fig. 3.
Table 2
MMP-9 rate depending on the course type and stage of disease
Course type Stage of disease Number of patients ММР-9 rate
RRMS
Exacerbation 26 381.54±22.19
Remission 45 122.05±7.82
SPMS
Progression 28 169.98±15.64
Stabilization 21 114.64±8.43
PPMS
Progression 8 147.03±6.78
Stabilization 7 121.96±10.90
Fig. 3. Dependence of MMP-9 rate on the course type and stage of disease
4. Conclusions
1. Matrix metalloproteinase-9 may be considered as an activity marker of the inflammatory 
process, a marker of immunocompetent cells, and as a BBB state indicator at MS.
2. Determination of MMP-9 rate may contribute to the monitoring of therapy efficacy in MS 
patients at different stages of the disease.
3. Decrease of level of MMP-9 during exacerbations of MS may serve as unfovarable prog-
nostic criterion and rate as predictor of chaging of types on progressive.
4. MMP-9 rate determination method may be recommended as part of diagnostic examina-
tion of MS patients in particular if neuroimaging is for some reasons not available.
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